Early Alzheimer's detection study using digital tools
Part of Brain & nervous system, Mental health clinical trials.
This study uses a digital tool to help detect early signs of Alzheimer's disease in people aged 50 and older. It aims to find high-risk individuals who may benefit from early monitoring.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years or older.
- You have lived in the community for at least one year and have medical records there.
- You do not have a known memory or thinking problem (like mild cognitive impairment or Alzheimer's) and are not taking medications for it.
- You can understand and communicate in Chinese.
- You are willing to take part in the study.
- You are at higher risk because of memory concerns, family history, or a known gene variant (APOE e4).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks for new ways to diagnose memory and thinking problems earlier. It involves a memory test, brain scan, and blood draw to find markers that could help identify cognitive disorders.
This study aims to find early signs of Alzheimer's in the community through blood tests and assessments. It's for people who can think clearly and agree to participate without major health issues.
This study invites people age 50+ who do not have dementia to do ongoing thinking tests online. If an online risk screen suggests you may be at higher risk, you may be referred for in-person body tests (biomarker assessment).
This study follows people who are closely related to someone diagnosed with Alzheimer’s to see who develops memory or brain changes over time. It may help researchers understand risk and early signs, which could guide prevention in families like yours.
This study is testing whether simple digital memory tests and blood tests can help find people who might qualify for anti-amyloid treatments (medications that target Alzheimer's-related proteins). It aims to make screening easier and faster, without needing a spinal tap or PET scan.
This study looks for brain/biological “signals” (biomarkers) that may identify Alzheimer’s disease earlier, including stages before clear symptoms. You may be followed for about 5 years, with repeated memory and thinking testing to see how these signs relate to future diagnosis.
Hear when a new Dementia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.